Trials / Completed
CompletedNCT02446717
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ABT-493 and ABT-530 With and Without Ribavirin in Adults With HCV Who Failed a Prior DAA Containing Therapy
A Randomized, Open-Label, Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 (or ABT-493/ABT-530) With and Without Ribavirin in Adults With Chronic Hepatitis C Virus (HCV) Infection Who Failed a Prior Direct-Acting Antiviral Agent (DAA)-Containing Therapy
- Status
- Completed
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 141 (actual)
- Sponsor
- AbbVie · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the efficacy and safety of ABT-493 and ABT-530 with or without ribavirin (RBV) in participants with chronic hepatitis C virus, (HCV)-infection who previously failed treatment with a direct acting antiviral (DAA)-containing regimen.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ABT-493, ABT-530 | ABT-493 (tablet) dosed with ABT-530 (tablet) |
| DRUG | ribavirin (RBV) | Tablet |
| DRUG | ABT-493/ABT-530 | Tablet; ABT-493 coformulated with ABT-530 |
Timeline
- Start date
- 2015-04-01
- Primary completion
- 2016-12-01
- Completion
- 2017-01-01
- First posted
- 2015-05-18
- Last updated
- 2017-09-15
- Results posted
- 2017-09-15
Source: ClinicalTrials.gov record NCT02446717. Inclusion in this directory is not an endorsement.